News

Entera Bio Granted Patent for Oral Parathyroid Hormone by EU Patent Authority

June 22, 2021 (Investorideas.com Newswire) Anavex Life Sciences shares traded 13% higher after the company reported that ANAVEX2-73 (blarcamesine) biomarker correlated highly with the predetermined efficacy endpoints in its Phase 2 clinical trial of adult patients with Rett syndrome.

What's your reaction?

Excited
0
Happy
0
In Love
0
Not Sure
0
Silly
0

Leave a reply

Your email address will not be published. Required fields are marked *

More in:News

Next Article:

0 %